Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study

Table 2 OSDI and GSS scores, clinical data, in vivo confocal microscopy

	OSDI score	GSS score	Schirmer I test (mm/5min)	BUT (sec)	Basal epithelial cell density (cell/mm²)	Stromal reflectiviy (grades 1 to 4)	Number of sub-basal nerves	Sub-basal nerves tortuosity (grades 0 to 4)	Sub-basal nerve reflectivity (grades 0 to 4)	Endothelial cell density (cell/mm²)
PF Tafluprost 0.0015% group	10±7.01	85.88±10.92	16.48±8.5	10.09±3.23	5700.91±401.95	2.11±0.82	4.33±1.39	2.17±0.8	2.07±0.8	2476.17±300.83
PF Timolol 0.1% group	12.01±8.74	84.79±11.93	14.13±10.53	10.31±2.86	5745.27±482.24	2.17±0.93	4.23±0.97	2.0±1.01	2.04±0.82	2394.13±310.88
Control group	0±0	99.75±1.10	15.63±4.41	12.12±1.81	5535.43±69.43	1.65±0.70	4.78±0.8	1.3±0.91	1.8±0.85	2360.80±54.65
P value
PF Tafluprost 0.0015% vs PF Timolol 0.1%	0.260	0.666	0.059	0.551	0.535	0.879	0.602	0.377	0.766	0.202
PF Tafluprost 0.0015% vs controls	< 0.0001	< 0.0001	0.548	0.261	0.037	0.006	0.037	<0.0001	0.126	0.105
PF Timolol 0.1% vs controls	<0.0001	<0.0001	0.118	0.026	0.014	0.008	0.003	0.002	0.223	0.715

Differences in OSDI and GSS score, Schirmer I test, BUT and basal epithelial cell density were tested by Mann Whitney test. Differences in stromal reflectivity, number of sub-basal nerves, sub-basal nerve tortuosity, sub-basal nerve reflectivity and endothelial cell density were tested by T-test. P values <0.05 were considered statistically significant
OSDI Ocular Surface Disease Index, GSS Glaucoma Symptoms Scale, BUT break up time, PF preservative free

ISSN: 1471-2415